BioCardia Files 8-K on Shareholder Nominations

TL;DR

BioCardia filed an 8-K about shareholder director nominations - board shakeup incoming?

AI Summary

On October 7, 2025, BioCardia, Inc. filed an 8-K report detailing shareholder nominations for its board of directors. The filing indicates that the company is addressing matters related to corporate governance and director elections.

Why It Matters

This filing signals potential changes in the company's board composition, which could impact strategic direction and governance.

Risk Assessment

Risk Level: medium — Filings related to board nominations can indicate internal disputes or strategic shifts that may affect the company's future performance.

Key Players & Entities

• BioCardia, Inc. (company) — Registrant
• October 7, 2025 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.001 B — ch registered Common Stock , par value $0.001 BCDA The Nasdaq Capital Market Indicat

Filing Documents

• bcda20251007_8k.htm (8-K) — 26KB
• 0001437749-25-030649.txt ( ) — 153KB
• bcda-20251007.xsd (EX-101.SCH) — 3KB
• bcda-20251007_def.xml (EX-101.DEF) — 11KB
• bcda-20251007_lab.xml (EX-101.LAB) — 15KB
• bcda-20251007_pre.xml (EX-101.PRE) — 11KB
• bcda20251007_8k_htm.xml (XML) — 3KB

08 Shareholder Director Nominations

Item 5.08 Shareholder Director Nominations. Annual Meeting of Stockholders BioCardia, Inc.'s (the "Company") Board of Directors (the "Board") has established Tuesday, December 2, 2025 at 9:00 a.m. Pacific Time as the date and time for the 2025 Annual Meeting of Stockholders of the Company (the "Annual Meeting"), to be held at the Wilson Sonsini Goodrich & Rosati, P.C., 650 Page Mill Road, Palo Alto, California 94304-1050. The Board also established the close of business on October 8, 2025 as the record date for the determination of stockholders entitled to receive notice of and to vote at the Annual Meeting. The attendance instructions for the Annual Meeting will be set forth in the Company's proxy statement for the Annual Meeting, to be electronically filed prior to the Annual Meeting with the U.S. Securities and Exchange Commission ("SEC"). Stockholder Nomination of Directors Because the Annual Meeting will be held more than 30 days from the anniversary date of the Company's last annual meeting of stockholders on May 20, 2024, in accordance with Rule 14a-5(f) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), the Company is hereby informing its stockholders of the following: For stockholders who desire to submit a proposal for consideration at the Annual Meeting and wish to have such proposal included in the Company's proxy statement, the Company has set a new deadline for the receipt of such proposals in accordance with Rule 14a-8 under the Exchange Act. To be considered timely, the proposal must be received at the Company's principal executive offices no later than October 17, 2025, which the Company has determined is a reasonable time before the Company begins to print and mail its proxy materials. Such stockholder proposals must also comply with the other requirements of Rule 14a-8 of the Exchange Act, the rules and regulations promulgated by the SEC and the Company's amended and restated bylaws, as applicable. In addition, if

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOCARDIA, INC. /s/ Peter Altman, Ph.D. Peter Altman, Ph.D. President and Chief Executive Officer Date: October 7, 2025

View Full Filing

View this 8-K filing on SEC EDGAR